M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza.

In each influenza season, a distinct group of young, otherwise healthy individuals with no risk factors succumbs to life-threatening infection. To better understand the cause for this, we analyzed a broad range of immune responses in blood from a unique cohort of patients, comprising previously heal...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Cole, S, Dunning, J, Kok, W, Benam, K, Benlahrech, A, Repapi, E, Martinez, F, Drumright, L, Powell, T, Bennett, M, Elderfield, R, Thomas, C, Dong, T, McCauley, J, Liew, F, Taylor, S, Zambon, M, Barclay, W, Cerundolo, V, Openshaw, P, McMichael, A, Ho, L
स्वरूप: Journal article
भाषा:English
प्रकाशित: American Society for Clinical Investigation 2017
विवरण
सारांश:In each influenza season, a distinct group of young, otherwise healthy individuals with no risk factors succumbs to life-threatening infection. To better understand the cause for this, we analyzed a broad range of immune responses in blood from a unique cohort of patients, comprising previously healthy individuals hospitalized with and without respiratory failure during one influenza season, and infected with one specific influenza A strain. This analysis was compared with similarly hospitalized influenza patients with known risk factors (total of n = 60 patients recruited). We found a sustained increase in a specific subset of proinflammatory monocytes, with high TNF-α expression and an M1-like phenotype (independent of viral titers), in these previously healthy patients with severe disease. The relationship between M1-like monocytes and immunopathology was strengthened using murine models of influenza, in which severe infection generated using different models (including the high-pathogenicity H5N1 strain) was also accompanied by high levels of circulating M1-like monocytes. Additionally, a raised M1/M2 macrophage ratio in the lungs was observed. These studies identify a specific subtype of monocytes as a modifiable immunological determinant of disease severity in this subgroup of severely ill, previously healthy patients, offering potential novel therapeutic avenues.